United States: Combination Products: Regulatory And Patent Issues You Should Consider Now

Products involving combinations of drugs, biological products, and medical devices are becoming increasingly prominent. Combination products can involve components that are physically, chemically, or otherwise combined (e.g., a monoclonal antibody with a therapeutic drug); components that are packaged together (e.g., a drug packaged with a delivery device); or components that are provided separately but intended to be used together (e.g., a photosensitizing drug and activating light source).1

Combination products can follow a variety of regulatory pathways, each with its own benefits and shortcomings. FDA notes that a product's pathway "can impact the regulatory processes for all aspects of product development and management, including preclinical testing, clinical investigation, marketing applications, manufacturing and quality control, adverse event reporting, promotion and advertising, and post-approval modifications."2 The most successful companies begin targeting a regulatory pathway from the earliest stages of development, based at least in part on the regulatory and patent considerations discussed in this article.

REGULATORY PATHWAYS FOR COMBINATION PRODUCTS

A combination product's regulatory pathway generally depends on its primary mode of action (PMOA), recently defined in the 21st Century Cures Act as "the single mode of action of a combination product expected to make the greatest contribution to the overall intended therapeutic effects of the combination product."3,4 FDA's Office of Combination Products (OCP) examines the product's modes of action, determines which is the PMOA, and then uses that to assign the product to a particular FDA center for premarket review and regulation.5

Classification is more complicated if the PMOA is not clearly identified or there are two independent, equally important modes of action. In these cases, OCP generally looks to the product's most critical safety and efficacy issues, classifying the product either in accordance with other products raising the same issues or based on which FDA center is most experienced with such issues.6

Drug-Lead Products

If a combination product is classified as a drug lead, OCP assigns it to FDA's Center for Drug Evaluation and Research (CDER) for premarket review and regulation.7 Companies with an innovative drug-lead product generally must file a new drug application (NDA), which can cost up to $2.4 million in FDA application fees alone and take one year or more for FDA review.8, 9 This is in addition to the years and millions of dollars spent in development before the NDA is even filed.10

Combination products approved under an NDA may be eligible to receive five years or more of exclusivity from FDA.11 But the primary advantage of having a drug lead in a combination product can be summarized in three words: the Orange Book. The FDA Orange Book lists drug-lead products, along with patents covering the products, their active ingredients, and methods of use.12, 13 Companies benefit from these listings, because they provide notice of the patents to the public and give rise to the patent-related protections of the Hatch-Waxman Act.14

Under Hatch-Waxman, an NDA holder can sue a company seeking to market a generic version of its drug-lead product before it otherwise might be able to. More specifically, a company seeking to market a generic version of a drug can avoid the lengthy and costly NDA process by filing an abbreviated new drug application (ANDA), which relies on the data reported in the NDA.15 An ANDA filer must certify that each patent listed in the Orange Book either will expire before the generic product goes on the market (paragraph III certification), or is invalid, unenforceable, or will not be infringed by the product (paragraph IV certification).16 If the ANDA filer makes a paragraph IV certification, the NDA holder can sue for patent infringement before the proposed generic product is made, used, or sold. In addition, paragraph IV suits trigger a stay where FDA cannot approve the generic product application for up to 30 months.17, 18

Biological-Lead Products

If a combination product is classified as a biological-product lead, it is not eligible for listing in the Orange Book, and OCP will assign it to FDA's Center for Biologics Evaluation and Research (CBER) for premarket review and regulation.19 Companies with an innovative biological-lead product generally must file a biologic license application (BLA), which can cost more than $260,000 in FDA application fees alone and take one year or more for FDA review.9, 20 This is in addition to the years and millions of dollars spent in development before the BLA is even filed.21

Combination products approved under a BLA may be eligible for 12 years or more of FDA exclusivity.22 FDA lists the products and some of their exclusivities in its Purple Book publication.23 Unlike the Orange Book for drug-lead products, the Purple Book does not include patents. BLAs instead implicate the patent protections of the Biologics Price Competition and Innovation Act (BPCIA).24

Under BPCIA, a BLA holder can sue a company seeking to market a generic version of its biological-lead product before it otherwise might be able to. Similar to drug-lead products, a company seeking to market a generic version of a biological-lead product might be able to avoid part of the time and cost associated with filing a BLA by filing an abbreviated application that relies on the BLA holder's data.25 This filing may trigger a "patent dance" whereby the applicant and BLA holder exchange information and arrive at a list of patents subject to a patent-infringement action.26 Unlike with Hatch-Waxman litigation for drug-lead products, BPCIA patent litigation does not trigger a regulatory stay of approval for the generic product.

Medical-Device Lead Products

If a combination product is classified as a medical-device lead, it is not eligible for listing in the Orange Book or the Purple Book, and OCP will assign it to FDA's Center for Devices and Radiological Health (CDRH) for premarket review and regulation.27 Companies with an innovative medical-device-lead product generally must file a premarket approval application (PMA), which can cost more than $260,000 in FDA application fees alone and take about one year for FDA review.9, 20 Although this is in addition to the time and money spent in development,28 such time and cost are generally less than with drug-lead and biological-lead products. In addition, if the product contains only a small change over a previously approved device, the company can reduce time and cost even further by filing a premarket notification (PMN) instead of a PMA.

Combination products with medical-device leads do not receive FDA exclusivities, and their only patent-related protection is the patent term itself. As such, a company might need to wait until the medical-device-lead product is made, used, or sold before suing for patent infringement. Medical-device-lead products are generally listed in the FDA Global Unique Device Identification Database (GUDID), which does not include patent information, although one of the database's goals is better detection of counterfeit devices.29

PURSUING A PARTICULAR REGULATORY PATHWAY

Companies should decide which regulatory pathway to pursue early on, based on their time and cost goals and their patent portfolios. While development and approval for drug-lead and biological-product-lead combination products is lengthy and expensive, pursuing them may come with FDA data exclusivities and patent-related protections, as discussed above, that make the time and cost worthwhile. Pursuing a drug lead or biological-product lead is more likely a strong choice if the combination product enjoys a robust patent portfolio. On the other hand, if the product does not have a robust patent portfolio, or a more timely approval at a lower cost is the goal, pursuing the medical-device-lead pathway might be the best strategy.

Once a company decides which pathway will likely be most beneficial for its product, it should take steps to ensure that OCP assigns the product to that pathway. The most obvious way to do this is to ensure that the product's PMOA corresponds to the desired lead. To the extent that a product's PMOA is unclear, a company can ask OCP to assign the product to its preferred pathway in a Request for Designation (RFD). A company might be able to influence OCP's decision about product lead by consistently characterizing the product's therapeutic effect as attributed to the preferred lead, by analogizing the product to other products that OCP previously assigned to that lead, or by emphasizing safety and effectiveness issues that call for the expertise of the preferred center. For example, if a company consistently emphasizes the product's drug component during patent prosecution as providing the most important therapeutic action, OCP might be influenced to assign the product to CDER. Under the recent 21st Century Cures Act, FDA now must provide a substantive rationale when it disagrees with a company's determination of a combination product's PMOA.30

The choice of regulatory pathway must be balanced against the ability to obtain and leverage a robust patent portfolio. The ability to obtain a robust portfolio might depend on whether the company disclosed the product or its therapeutic action before it filed the patent application with the US Patent and Trademark Office (USPTO). For example, statements about a product at a trade show or in a peer-reviewed publication might preclude a company from securing a patent for the product. The ability to leverage a robust patent portfolio might depend on whether the company made statements to FDA that contradict statements in the patents or made to the USPTO during prosecution. For example, companies should take care in making statements when seeking authorization for human testing of a drug-lead product, submitting proposed labels to FDA for biological-lead products, or seeking approval for a new medical-device-lead product that relies on a predicate device. Companies developing combination products should strive for open communication and strategic coordination among scientists, individuals tasked with preparing FDA submissions, and individuals tasked with obtaining and leveraging the company's patents.

CONCLUSION

Although combination products raise challenges for FDA and companies alike, they also can provide opportunities for companies that strategize from the earliest stages to pursue the most beneficial regulatory pathway for their products. In developing a combination-product strategy, companies should consider regulatory and patent issues, including how these issues might be affected by ever-changing laws and regulations.

Originally printed in  Pharmaceutical Technology on February 23, 2017.

Footnotes

1 FDA, Frequently Asked Questions About Combination Products (Oct. 20, 2016) (citing Code of Federal Regulations, Title 21, Section 3.2(e)), accessed Feb. 6, 2017.

2 FDA, About Combination Products (Sept. 8, 2016), accessed Feb. 6, 2017.

3 21st Century Cures Act of 2016, Pub. L. No. 114-255, § 3038 (amending United States Code, Title 21, Section 353(g)).

4 Code of Federal Regulations, Title 21, Section 3.2(m).

5 Code of Federal Regulations, Title 21, Section 3.4.

6 Code of Federal Regulations, Title 21, Section 3.4(b).

7 Code of Federal Regulations, Title 21, Section 3.4(a)(1).

8 FDA, Prescription Drug User Fee Rates for Fiscal Year 2016, Fed. Reg. 80 (148), 46028–46031 (Aug. 3, 2015).

9 FDA, FY2015 Performance Report to Congress for the Office of Combination Products 14-15 (2016), accessed Feb. 6, 2017.

10 J. A. DiMasi et al., J. Health Econ. 47 (20) (2016).

11 Code of Federal Regulations, Title 21, Section 314.108.

12 Code of Federal Regulations, Title 21, Section 314.53(b).

13 FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, accessed Feb. 6, 2017.

14 Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (amending United States Code, Title 21, Section 355).

15 United States Code, Title 21, Section 355(j).

16 United States Code, Title 21, Section 355(j)(2)(A).

17 United States Code, Title 21, Section 355(j)(5)(B)(iii).

18 United States Code, Title 21, Section 355(c)(3)(E)(ii) (providing that the thirty-month period is extended in certain circumstances).

19 Code of Federal Regulations, Title 21, Section 3.4(a)(3).

20 FDA, Medical Device User Fee Rates for Fiscal Year 2016, Fed. Reg. 80 (148), 46033–46035 (Aug. 3, 2015).

21 J. A. DiMasi and H. G. Grabowski, Manage. Decis. Econ. 28 (469) (2007).

22 United States Code, Title 42, Section 262(k)(7)(A).

23 FDA, Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations.

24 Biologics Price Competition and Innovation Act of 2009, in the Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119, 804-21 (2010) (amending United States Code, Title 42, Section 262).

25 United States Code, Title 42, Section 262(k).

26 United States Code, Title 42, Section 262(l).

27 Code of Federal Regulations, Title 21, Section 3.4(a)(2).

28 Josh Makower, et al., FDA Impact on US Medical Technology Innovation (November 2010), accessed Feb. 6, 2017.

29 FDA, Unique Device Identification System, Fed. Reg. 78 (185), 58786–58787 (Sept. 24, 2013).

30 21st Century Cures Act of 2016, Pub. L. No. 114-255 § 3038(a)(4) (amending United States Code, Title 21, Section 353(g)).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
2 Nov 2017, Webinar, Washington, DC, United States

Join us for a two-part webinar series exploring recent developments in machine learning and other technologies that have greatly advanced artificial intelligence (AI) since its origins more than 50 years ago.

9 Nov 2017, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan attorneys Adriana Burgy, Chris Johns, and Kai Rajan will discuss the Examiner Count System and provide strategies for interacting with examiners.

15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.